Prevention and treatment of heterotopic ossification after spinal cord injury

Kresimir Banovac, Andrew L. Sherman, Irene M. Estores, Filip Banovac

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background/Objectives: Heterotopic ossification (HO) is a frequent, irreversible complication after spinal cord injury (SCI). The objective of this article is to explain the etiology of HO; present new advances in prevention, diagnosis, and management of this complication; and provide a suggested algorithm for clinical management. Etiology: Although still hypothetical, trauma and overexpression of bone morphogenic protein(s) in traumatized soft tissue appear to play important roles as initiating factors of HO. Prevention: Preventive use of nonsteroidal antiinflammatory agents (NSAIDs) reduces the incidence of HO by a magnitude of 2 to 3. Management: Early determination of serum creatine phosphokinase may have a diagnostic value in predicting the onset and severity of HO, and an NSAID may be added to etidronate therapy in the initial inflammatory phase of HO formation until C-reactive protein levels return to normal range. Surgery is indicated in a subset of patients, and a regimen that includes radiation therapy may prevent postoperative recurrence. Conclusion: Significant progress has been made in the early prevention and management of HO. Further studies are needed to elucidate the etiology.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalJournal of Spinal Cord Medicine
Volume27
Issue number4
StatePublished - Dec 1 2004

Fingerprint

Heterotopic Ossification
Spinal Cord Injuries
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Etidronic Acid
Creatine Kinase
C-Reactive Protein
Reference Values
Radiotherapy
Bone and Bones
Recurrence
Incidence
Wounds and Injuries
Serum

Keywords

  • C-reactive protein
  • Creatine phosphokinase
  • Etidronate
  • Heterotopic ossification
  • NSAID
  • Prevention
  • Roficoxib
  • Spinal cord injuries

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Prevention and treatment of heterotopic ossification after spinal cord injury. / Banovac, Kresimir; Sherman, Andrew L.; Estores, Irene M.; Banovac, Filip.

In: Journal of Spinal Cord Medicine, Vol. 27, No. 4, 01.12.2004, p. 376-382.

Research output: Contribution to journalArticle

Banovac, Kresimir ; Sherman, Andrew L. ; Estores, Irene M. ; Banovac, Filip. / Prevention and treatment of heterotopic ossification after spinal cord injury. In: Journal of Spinal Cord Medicine. 2004 ; Vol. 27, No. 4. pp. 376-382.
@article{614c5186289046d99d465e81377e53e1,
title = "Prevention and treatment of heterotopic ossification after spinal cord injury",
abstract = "Background/Objectives: Heterotopic ossification (HO) is a frequent, irreversible complication after spinal cord injury (SCI). The objective of this article is to explain the etiology of HO; present new advances in prevention, diagnosis, and management of this complication; and provide a suggested algorithm for clinical management. Etiology: Although still hypothetical, trauma and overexpression of bone morphogenic protein(s) in traumatized soft tissue appear to play important roles as initiating factors of HO. Prevention: Preventive use of nonsteroidal antiinflammatory agents (NSAIDs) reduces the incidence of HO by a magnitude of 2 to 3. Management: Early determination of serum creatine phosphokinase may have a diagnostic value in predicting the onset and severity of HO, and an NSAID may be added to etidronate therapy in the initial inflammatory phase of HO formation until C-reactive protein levels return to normal range. Surgery is indicated in a subset of patients, and a regimen that includes radiation therapy may prevent postoperative recurrence. Conclusion: Significant progress has been made in the early prevention and management of HO. Further studies are needed to elucidate the etiology.",
keywords = "C-reactive protein, Creatine phosphokinase, Etidronate, Heterotopic ossification, NSAID, Prevention, Roficoxib, Spinal cord injuries",
author = "Kresimir Banovac and Sherman, {Andrew L.} and Estores, {Irene M.} and Filip Banovac",
year = "2004",
month = "12",
day = "1",
language = "English",
volume = "27",
pages = "376--382",
journal = "Journal of Spinal Cord Medicine",
issn = "1079-0268",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - Prevention and treatment of heterotopic ossification after spinal cord injury

AU - Banovac, Kresimir

AU - Sherman, Andrew L.

AU - Estores, Irene M.

AU - Banovac, Filip

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Background/Objectives: Heterotopic ossification (HO) is a frequent, irreversible complication after spinal cord injury (SCI). The objective of this article is to explain the etiology of HO; present new advances in prevention, diagnosis, and management of this complication; and provide a suggested algorithm for clinical management. Etiology: Although still hypothetical, trauma and overexpression of bone morphogenic protein(s) in traumatized soft tissue appear to play important roles as initiating factors of HO. Prevention: Preventive use of nonsteroidal antiinflammatory agents (NSAIDs) reduces the incidence of HO by a magnitude of 2 to 3. Management: Early determination of serum creatine phosphokinase may have a diagnostic value in predicting the onset and severity of HO, and an NSAID may be added to etidronate therapy in the initial inflammatory phase of HO formation until C-reactive protein levels return to normal range. Surgery is indicated in a subset of patients, and a regimen that includes radiation therapy may prevent postoperative recurrence. Conclusion: Significant progress has been made in the early prevention and management of HO. Further studies are needed to elucidate the etiology.

AB - Background/Objectives: Heterotopic ossification (HO) is a frequent, irreversible complication after spinal cord injury (SCI). The objective of this article is to explain the etiology of HO; present new advances in prevention, diagnosis, and management of this complication; and provide a suggested algorithm for clinical management. Etiology: Although still hypothetical, trauma and overexpression of bone morphogenic protein(s) in traumatized soft tissue appear to play important roles as initiating factors of HO. Prevention: Preventive use of nonsteroidal antiinflammatory agents (NSAIDs) reduces the incidence of HO by a magnitude of 2 to 3. Management: Early determination of serum creatine phosphokinase may have a diagnostic value in predicting the onset and severity of HO, and an NSAID may be added to etidronate therapy in the initial inflammatory phase of HO formation until C-reactive protein levels return to normal range. Surgery is indicated in a subset of patients, and a regimen that includes radiation therapy may prevent postoperative recurrence. Conclusion: Significant progress has been made in the early prevention and management of HO. Further studies are needed to elucidate the etiology.

KW - C-reactive protein

KW - Creatine phosphokinase

KW - Etidronate

KW - Heterotopic ossification

KW - NSAID

KW - Prevention

KW - Roficoxib

KW - Spinal cord injuries

UR - http://www.scopus.com/inward/record.url?scp=7944229172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944229172&partnerID=8YFLogxK

M3 - Article

C2 - 15484668

AN - SCOPUS:7944229172

VL - 27

SP - 376

EP - 382

JO - Journal of Spinal Cord Medicine

JF - Journal of Spinal Cord Medicine

SN - 1079-0268

IS - 4

ER -